Mr. Kidd is president and chief executive officer of Aptinyx, as well as a member of the company’s board of directors. Prior to joining Aptinyx in 2017 as chief commercial officer and then chief operating officer, he was with Baxter International for over ten years, most recently as senior vice president of strategy and business development. Previously he held a number of commercial leadership positions including general manager of Baxter Canada, global franchise head for surgical care, and general manager of US anesthesia and cardiovascular. Before joining Baxter he worked at Boston Consulting Group both in London and then Chicago focused on pharmaceutical and other healthcare clients. Mr. Kidd received a BM BCh medical degree from the University of Oxford and a BA in medical sciences from the University of Cambridge.

• 

  President in Aptinyx

  Discovering & Developing Innovative Therapies for Challenging Disorders of the Brain & Nervous System

• 

  Chief Executive Officer (CEO) in Aptinyx

  Discovering & Developing Innovative Therapies for Challenging Disorders of the Brain & Nervous System

• 

  Board of Director in Aptinyx

  Discovering & Developing Innovative Therapies for Challenging Disorders of the Brain & Nervous System

• 

  Chief Executive Officer (CEO) in Tentarix Biotherapeutics

  Enabling intelligent therapies with multifunctional biologics